Woodline Partners »

Immunome shares owned by Woodline Partners

Quarter-by-quarter ownership of Immunome (IMNM) shares owned by Woodline Partners from 13F filings

Historical chart of Woodline Partners investment in Immunome

Tip: Access up to 7 years of quarterly data

All positions including Immunome held by Woodline Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Immunome by Woodline Partners

Quarter filed Position value Share count Share price at filing
2024-03-31 $33M 1.3M 24.68

More positions owned by Woodline Partners

Eli Lilly & Co. (LLY)
Te Connectivity SHS (TEL)
Regeneron Pharmaceuticals (REGN)
Encana Corporation (OVV)
Analog Devices (ADI)
Avnet (AVT)
Merck & Co (MRK)
Revolution Medicines (RVMD)
Zimmer Holdings (ZBH)
Meta Platforms Cl A (META)
Roivant Sciences SHS (ROIV)
Abbvie (ABBV)
Enerplus Corp (ERF)
Permian Resources Corp Class A Com (PR)
Amazon (AMZN)

View all positions for Woodline Partners

Top funds holding Immunome

Redmile Group
FMR
EcoR1 Capital
T. Rowe Price Associates
Vanguard Group
Point72 Asset Management
Henderson Group
T. Rowe Price Investment Management
Woodline Partners
Avidity Partners Management
BlackRock
Tang Capital Management
Brown Advisory Holdings Incorporated
Sofinnova Ventures
Farallon Capital Management

View all funds holding Immunome